- Home
- BIRD vs VRCA Comparison
BIRD vs VRCA Comparison
Compare BIRD & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIRD
- VRCA
- Stock Information
- Founded
- BIRD 2015
- VRCA 2013
- Country
- BIRD United States
- VRCA United States
- Employees
- BIRD N/A
- VRCA N/A
- Industry
- BIRD Apparel
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- BIRD Consumer Discretionary
- VRCA Health Care
- Exchange
- BIRD Nasdaq
- VRCA Nasdaq
- Market Cap
- BIRD 39.1M
- VRCA 32.7M
- IPO Year
- BIRD 2021
- VRCA 2018
- Fundamental
- Price
- BIRD $4.73
- VRCA $4.52
- Analyst Decision
- BIRD Buy
- VRCA Hold
- Analyst Count
- BIRD 2
- VRCA 2
- Target Price
- BIRD $11.00
- VRCA N/A
- AVG Volume (30 Days)
- BIRD 90.4K
- VRCA 93.9K
- Earning Date
- BIRD 11-06-2025
- VRCA 11-14-2025
- Dividend Yield
- BIRD N/A
- VRCA N/A
- EPS Growth
- BIRD N/A
- VRCA N/A
- EPS
- BIRD N/A
- VRCA N/A
- Revenue
- BIRD $160,639,000.00
- VRCA $30,829,000.00
- Revenue This Year
- BIRD N/A
- VRCA $332.45
- Revenue Next Year
- BIRD $4.65
- VRCA $12.85
- P/E Ratio
- BIRD N/A
- VRCA N/A
- Revenue Growth
- BIRD N/A
- VRCA 234.73
- 52 Week Low
- BIRD $3.93
- VRCA $3.28
- 52 Week High
- BIRD $12.85
- VRCA $13.60
- Technical
- Relative Strength Index (RSI)
- BIRD 31.79
- VRCA 62.57
- Support Level
- BIRD $4.38
- VRCA $3.64
- Resistance Level
- BIRD $9.19
- VRCA $4.02
- Average True Range (ATR)
- BIRD 0.57
- VRCA 0.31
- MACD
- BIRD -0.32
- VRCA 0.12
- Stochastic Oscillator
- BIRD 5.43
- VRCA 90.07
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.